**China Medical System Holdings Ltd. Receives NMPA Approval to Begin Clinical Trials for Innovative COPD Drug** China Medical System Holdings Ltd. announced it has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials of its innovative drug, MG-K10, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). MG-K10 is a long-acting anti-IL-4Rα humanized monoclonal antibody that targets type 2 inflammatory diseases by blocking IL-4 and IL-13 signaling pathways. The company holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for MG-K10 in Mainland China, Hong Kong, Macao, Taiwan, and Singapore, following a collaboration agreement with Mabgeek Biotech and its subsidiary. The approval marks a significant step forward in expanding China Medical System's respiratory product portfolio and providing new treatment options for COPD patients in the region. No grant or funding from external agencies or multiple organizations was announced in connection with this regulatory approval.